Entrada Therapeutics, Inc. (NASDAQ:TRDA – Get Free Report) saw a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 1,650,000 shares, a decrease of 19.1% from the September 30th total of 2,040,000 shares. Approximately 7.6% of the shares of the stock are short sold. Based on an average daily trading volume, of 139,800 shares, the short-interest ratio is currently 11.8 days.
Entrada Therapeutics Stock Down 0.5 %
TRDA traded down $0.09 on Tuesday, reaching $17.28. 77,284 shares of the company traded hands, compared to its average volume of 103,970. The company has a market cap of $642.82 million, a P/E ratio of 5.82 and a beta of -0.25. The firm has a fifty day simple moving average of $16.16 and a two-hundred day simple moving average of $15.37. Entrada Therapeutics has a one year low of $10.75 and a one year high of $18.17.
Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.90. Entrada Therapeutics had a return on equity of 35.16% and a net margin of 43.63%. The firm had revenue of $94.69 million during the quarter, compared to analyst estimates of $55.00 million. On average, equities analysts forecast that Entrada Therapeutics will post 0.68 earnings per share for the current year.
Insider Activity at Entrada Therapeutics
Hedge Funds Weigh In On Entrada Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. The Manufacturers Life Insurance Company lifted its stake in Entrada Therapeutics by 3.9% in the second quarter. The Manufacturers Life Insurance Company now owns 57,098 shares of the company’s stock worth $814,000 after acquiring an additional 2,146 shares during the period. US Bancorp DE bought a new stake in shares of Entrada Therapeutics in the 3rd quarter valued at about $42,000. Acadian Asset Management LLC purchased a new stake in shares of Entrada Therapeutics in the 1st quarter worth approximately $79,000. Rhumbline Advisers increased its holdings in Entrada Therapeutics by 25.3% during the second quarter. Rhumbline Advisers now owns 36,940 shares of the company’s stock valued at $526,000 after buying an additional 7,452 shares during the period. Finally, SG Americas Securities LLC bought a new position in Entrada Therapeutics in the third quarter worth approximately $156,000. Institutional investors own 86.39% of the company’s stock.
Wall Street Analysts Forecast Growth
Several research analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Entrada Therapeutics in a research note on Wednesday, August 14th. Oppenheimer reissued an “outperform” rating and issued a $25.00 price objective on shares of Entrada Therapeutics in a research report on Monday, August 26th.
View Our Latest Report on Entrada Therapeutics
About Entrada Therapeutics
Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.
Recommended Stories
- Five stocks we like better than Entrada Therapeutics
- How to Start Investing in Real Estate
- Is McDonald’s Stock a Smart Buy After Sell-Off and Earnings?
- Why Are Stock Sectors Important to Successful Investing?
- QuantumScape: Solid State EV Batteries Nearing Commercialization
- How to Invest in the FAANG Stocks
- MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.